Clinical Trial Finder

Inclusion criteria:

• - Personally signed informed consent document.

• - Male or female, age ≥18 years.

• - Relapsed or refractory ROR1+ malignancies.

• - ECOG performance status ≤2.

• - Adequate organ function.

• - Bilirubin ≤1.5 x ULN (unless Gilbert's syndrome).

• - AST and ALT ≤2.5 x ULN (if no hepatic CLL or MCL), or AST and ALT ≤5 x ULN (if hepatic CLL or MCL).

• - APTT and PT ≤1.5 x ULN.

• - ANC ≥0.5 x 10^9 /L (without growth factors) and platelets ≥ 30 x 10^9 /L (without transfusion).

• - Serum creatinine ≤2 x ULN.

• - Estimated creatinine clearance ≥30 mL/min.

• - In females of childbearing potential, a negative serum pregnancy test.

• - For both males and females, willingness to use adequate contraception.

• - Willingness and ability to comply with study procedures.

Exclusion Criteria:

• - Richter's transformation.

• - CNS or leptomeningeal active disease.

• - High tumour bulk as defined in the protocol.

• - Allogeneic or autologous organ transplant within prior 6 months.

• - Uncontrolled autoimmune haemolytic anaemia or idiopathic thrombocytopenic purpura within 8 weeks of screening.

• - Clinically significant neurological disease.

• - Clinically significant cardiovascular disease or ECG abnormalities.

• - Severe chronic lung disease.

• - Positive test at Screening for HIV, hepatitis B or hepatitis C infection.

• - Any other concurrent cancer or cancer treatments.

• - Uncontrolled ongoing infection.

• - Recent major surgery.

• - Concurrent participation in another clinical trial, or experimental therapy within 5 half-lives of Screening.

• - Pregnant or currently breastfeeding.

• - Any other medical condition that in the opinion of the investigator contraindicates participation in the study.

Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1) is a protein which is expressed at high levels on many types of cancers but is absent or expressed at low levels in normal adult organs. NVG-111 is a bispecific antibody T cell engager, comprising tandem single chain variable fragments (scFv), one arm binding to ROR1 on cancer cells, the other to cell surface CD3 on lymphocytes. Dual binding of NVG-111 causes MHC-independent immunological synapse formation, releasing perforins, granzyme B and cytokines, resulting in targeted killing of the cancer cells. This is a Phase 1 first in human study to assess the safety, pharmacokinetics and efficacy of NVG-111 in patients with subjects with relapsed/refractory ROR1+ malignancies. A range of doses will be studied in sequential cohorts to understand safety, pharmacokinetics and pharmacodynamics of the drug and establish the recommended phase 2 dose (RP2D). At each dose level, patients will receive 3 cycles of NVG-111 by continuous intravenous infusion, each cycle consists of 21 days treatment. Additional cycles may be given depending on the response seen. All patients will have a safety follow up visit 4 weeks after completion of treatment with NVG-111, and will then enter long term follow up for up to two years to evaluate the duration of efficacy.

Arms

Interventions